抗肿瘤抗生素平阳霉素研究与临床应用40年

Antitumor antibiotic pingyangmycin:research and clinical use for 40 years

平阳霉素是由我国学者自主研制并投入临床应用的抗肿瘤药物,是博来霉素类抗肿瘤药物的新品种。日本报道的博来霉素(bleomycin)是含有13种组分的复合物,其中以A2为主要组分,而A5只占1%左右;平阳霉素则是单一A5组分的制品。平阳霉素的研究开发与临床应用经历了长期的过程。1969年从浙江省平阳县土壤分离发现产生菌,1978年通过鉴定投产并进入临床应用,1982年获国家发明奖二等奖,平阳霉素被收载于中国药典,1994年进入首批国家基本药物目录,迄今已经历40年。平阳霉素已成为我国临床较常用的抗癌药物。平阳霉素用于制备抗体靶向药物的潜在价值正在进行研究。

Pingyangmycin （ PYM）, an antitumor antibiotic of clinically available, was developed in China. As an antitumor agent, PYM is a member of bleomycin family with separate entity. Consisting of single component AS, PYM is different from bleomycin that is composed of 13 components with A2 as the major component. The research and clinical use of PYM have been lasting for 40 years. The producing Streptomyces strain was firstly isolated from a soil sample collected in Pingyang County, Zhejiang province of China in 1969. PYM was approved for clinical use in 1978. The study of PYM obtained National Invention Prize （2nd grade） in 1982. Since 1994, PYM has been documented as National Essential Drug in China. The studies of its potential use in the preparation of antibody-based drugs for targeted cancer therapy are in progress.